Megestrol acetate for cachexia–anorexia syndrome. A systematic review
Abstract In 1993, megestrol acetate (MA) was approved by the US Food and Drug Administration for the treatment of anorexia, cachexia, or unexplained weight loss in patients with acquired immunodeficiency syndrome. The mechanism by which MA increases appetite is unknown, and its effectiveness for ano...
Main Authors: | Vicente Ruiz‐García, Eduardo López‐Briz, Rafael Carbonell‐Sanchis, Sylvia Bort‐Martí, José Luis Gonzálvez‐Perales |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-06-01
|
Series: | Journal of Cachexia, Sarcopenia and Muscle |
Subjects: | |
Online Access: | https://doi.org/10.1002/jcsm.12292 |
Similar Items
-
Efficacy of megestrol acetate in treatment of 21 young patients with endometrial adenocarcinoma
by: Eftekhar Z, et al.
Published: (2007-05-01) -
New Biopolymer Nanoparticles Improve the Solubility of Lipophilic Megestrol Acetate
by: Malwina Lachowicz, et al.
Published: (2016-02-01) -
Adjuvant chemotherapy of megestrol acetate in advanced breast cancer: A meta-analysis
by: Yanping Shui, et al.
Published: (2015-04-01) -
The role of estrogen and progesterone receptors in response rate to megestrol acetate: conservative treatment of stage Ia endometrial adenocarcinoma
by: Yarandi F, et al.
Published: (2010-12-01) -
Cancer anorexia-cachexia syndrome
by: S Ruengdit, et al.
Published: (2009-12-01)